

Tuberculosis profile: Pakistan

Population 2021: 231 million

Estimates of TB burden*, 2021

	Number	(Rate per 100 000 population)
Total TB incidence	611 000 (445 000-803 000)	264 (192-347)
HIV-positive TB incidence	15 000 (9 900-20 000)	6.3 (4.3-8.8)
MDR/RR-TB incidence**	36 000 (6 200-65 000)	15 (2.7-28)
HIV-negative TB mortality	48 000 (38 000-59 000)	21 (16-25)
HIV-positive TB mortality	2 100 (1 700-2 600)	0.93 (0.74-1.1)

Estimated proportion of TB cases with MDR/RR-TB*, 2021

New cases	5.9% (2.5-12)
Previously treated cases	4.4% (3.8-4.9)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2021	55% (42-76)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2021	8% (6-12)

TB case notifications, 2021

Total new and relapse	339 256
- % tested with rapid diagnostics at time of diagnosis	55%
- % with known HIV status	52%
- % pulmonary	82%
- % bacteriologically confirmed [^]	52%
- % children aged 0-14 years	13%
- % women (aged ≥15 years)	40%
- % men (aged ≥15 years)	47%
Total cases notified	343 024

TB/HIV care in new and relapse TB patients, 2021

	Number	(%)
Patients with known HIV status who are HIV-positive	1 013	0.58%
- on antiretroviral therapy	637	63%

Drug-resistant TB care**, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases [^]	92%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases [^]	84%
Laboratory-confirmed cases - MDR/RR-TB ^{^^}	3 138
Patients started on treatment - MDR/RR-TB ^{^^^}	2 878
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^{^^}	838
Patients started on treatment - pre-XDR-TB or XDR-TB ^{^^^}	838
MDR/RR-TB cases tested for resistance to any fluoroquinolone	2 140

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2020	94%	272 990
Previously treated cases, excluding relapse, registered in 2020	84%	3 746
HIV-positive TB cases registered in 2020	82%	556
MDR/RR-TB cases started on second-line treatment in 2019	73%	2 527
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019	67%	407


TB preventive treatment, 2021

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	3% (2.8-3.3)


Funding for TB

Funding for TB, 2021 (US\$ millions)	47
- % domestic funding	8%
- % international funding	92%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




HIV-negative TB mortality (Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2021 (Number)



Cases attributable to five risk factors, 2021 (Number)



Funding for TB (US\$ millions)



** Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.*
*** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone*
^ Calculated for pulmonary cases only
^^ Includes cases with unknown previous TB treatment history
^^^ Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed